[Report] Antidiabetics Commercial Insight Market Research, Trends, Analysis TOC

Market definition for this report
Current market situation: National markets
The insulin market: Humalog; NovoLin; Lantus; Humulin; NovoRapid/NovoLog; Outlook
Thiazolidinediones: Actos; Avandia
Sulfonylureas: Amaryl; Glucotrol XL
Biguanides: Glucophage
Strategic scoping and focus

Current and future opportunities and threats in the antidiabetics market: Global opportunities and threats; Opportunities; Threats; US: current market assessment; Overview; US market issues; Japan: current market assessment; Overview; Japan market issues; Europe: current market assessment; Overview; Europe market issues
Summary of environmental issues affecting the antidiabetic market size

Assumptions and events

Ongoing trends; Increasing market size; Trial results; PROACTIVE; CHICAGO and PERISCOPE; DREAM; ACCORD; ADOPT; ORIGIN; NAVIGATOR; New product launches; Byetta and Exenatide LAR; Symlin; Pargluva; Vildagliptin; Liraglutide; Exubera; AERx iDMS; Patent expiries
Limitations of data
Forecasts

Introduction
Case study 1: Aventis: Building a successful insulin portfolio; Competitive landscape; Lantus; Lantus strategic analysis; Conclusion; Apidra; Exubera; The basis of commercial success
Case study 2: BMS: Managing the lifecycle of Glucophage; Patent protection strategies; DepoMed announces lawsuit against BMS for Glucophage XR patent infringement; Study published in JAMA reveals Glucophage is prescribed to patients with heart and kidney disorders, despite black box warning of lactic acidosis side-effect; Merck Sante announces a trademark and patent-licensing agreement with Sumitomo Pharmaceuticals for the development and commercialization of Glucophage and Glucophage XR in Japan; BMS announces FDA approval of 750mg dose of Glucophage XR; Strategic analysis

Bibliography: Epidemiology; Clinical trial data
Report methodology: Standard units; Japanese market data
About Datamonitor: About Datamonitor Healthcare; About the Cardiovascular Disease analysis team; Disclaimer

Table 1: Global sales in the antidiabetic market by drug class, 2004
Table 2: Global sales of the leading branded insulin families, 2003-04
Table 3: Global sales of the leading branded TZDs, 2003-04
Table 4: Global sales of the leading branded sulfonylureas, 2003-04
Table 5: Global sales of the leading branded biguanide compared to generics, 2003-04
Table 6: Future prevalence of type 1 and type 2 diabetes in the seven major markets, 2004-12
Table 7: Prevalence of obesity in the seven major markets by age (000s), 2003
Table 8: US sales and growth of drug classes
Table 9: Japan sales and growth of drug classes
Table 10: EU5 sales and growth of drug classes
Table 11: Patent expiry dates used in forecasting antidiabetics market
Table 12: Key Lantus events
Table 13: Key Glucophage and Glucophage XR events
Table 14: Annual cost of therapy for Glucophage brands versus generics
Table 15: Humulin: key facts
Table 16: Humalog: key facts
Table 17: NovoLin: key facts
Table 18: NovoLog: key facts
Table 19: Lantus: key facts
Table 20: Actos: key facts
Table 21: Avandia: key facts
Table 22: Amaryl: key facts
Table 23: Glucotrol XL: key facts
Table 24: Glucophage and Glucophage XR: key facts

Figure 1: Sales and growth for antidiabetic drug classes in the seven major markets, 2003-04
Figure 2: Share of antidiabetics market represented by each of the seven major markets in 2004
Figure 3: Pioglitazones effects on triglyceride and HDL cholesterol levels
Figure 4: Proportion of population 20-39 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
Figure 5: Proportion of population 40-59 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
Figure 6: Proportion of population 60-79 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
Figure 7: Annual US sales of the antidiabetic drug classes, 2001-04
Figure 8: Annual Japan sales of the antidiabetic drug classes, 2001-04
Figure 9: Annual EU5 sales of the antidiabetic drug classes, 2001-04
Figure 10: Summary of environmental issues
Figure 11: SWOT analysis for Lantus
Figure 12: SWOT analysis for the Glucophage franchise

Commercial Insight: Antidiabetics - Billion Dollar Drugs, Pipeline Dreams?